STOCK-BASED COMPENSATION (Tables)

12 Months Ended

Dec. 30, 2018

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Schedule of impact on results of operations of recording stock-based compensation expense

The impact on the Company’s results of operations of recording stock-based compensation expense for fiscal years 2018, 2017, and 2016 was as follows (in thousands):

	Fiscal Years
	2018		2017		2016
Cost of revenue	$	129	$	121	$	132
Research and development		760		614		658
Selling, general and administrative		1,012		706		794
Total costs and expenses	$	1,901	$	1,441	$	1,584

Schedule of shares available for grant

The following table summarizes the shares available for grant under the 2009 Plan:

	Shares Available for Grant
	(in thousands)
Balance at December 31, 2017		3,899
Authorized		4,000
Options granted		—
Options forfeited or expired		141
RSUs granted		(1,539	)
RSUs forfeited		259
Balance at December 30, 2018		6,760

Schedule of stock options outstanding and stock option activity and related weighted average exercise price

The following table summarizes stock options outstanding and stock option activity under the 2009 Plan, and the related weighted average exercise price, for 2018, 2017 and 2016:

	Number of Shares			Weighted Average Exercise Price		Weighted Average Remaining Term		Aggregate Intrinsic Value
	(in thousands)					(in years)		(in thousands)
Balance outstanding at January 3, 2016		5,266		$	2.64		4.56
Granted		842			0.86
Forfeited or expired		(1,129	)		2.61
Exercised		-			-
Balance outstanding at January 1, 2017		4,979			2.35		4.06
Granted		—			—
Forfeited or expired		(1,356	)		3.07
Exercised		(65	)		1.31
Balance outstanding at December 31, 2017		3,558			2.09		4.34
Granted		—			—
Forfeited or expired		(141	)		1.80
Exercised		(216	)		0.90
Balance outstanding at December 30, 2018		3,201		$	2.18		3.70	$	-
Exercisable at December 30, 2018		2,868		$	2.33		3.24	$	-
Vested and expected to vest at December 30, 2018		3,153		$	2.20		3.64	$	-

Schedule of significant price ranges of options outstanding, related weighted average exercise prices and contractual life information

Significant exercise price ranges of options outstanding, related weighted average exercise prices and contractual life information at the end of 2018 were as follows:

		Options Outstanding						Options Exercisable
Range of Exercise Prices		Options Outstanding		Weighted Average Remaining Contractual Life		Weighted Average Exercise Price		Options Vested and Exercisable		Weighted Average Exercise Price
		(in thousands)		(in years)				(in thousands)
$0.78			4		0.18	$	0.78		4	$	0.78
$0.86			726		7.69		0.86		408		0.86
$	1.32		66		6.90		1.32		51		1.32
$1.63			545		0.27		1.63		545		1.63
$2.17 - $2.65			287		3.66		2.25		287		2.25
$2.78			944		1.93		2.78		944		2.78
$2.82 - $3.36			222		4.43		3.16		222		3.16
$3.39			237		4.73		3.39		237		3.39
$3.48			105		3.36		3.48		105		3.48
$3.82			65		5.08		3.82		65		3.82
$0.78 - $3.82			3,201		3.70	$	2.18		2,868	$	2.33

Schedule of weighted average assumptions included in estimated fair value calculations for stock option grants

The following weighted average assumptions are included in the estimated fair value calculations for stock option grants:

	Fiscal Years
	2018		2017		2016
Expected term (years)		—		—		7.1
Risk-free interest rate		—		—		1.40	%
Expected volatility		—		—		52	%
Expected dividend		—		—		—

Schedule of share-based compensation related to RSU

The following table summarizes RSU’s activity under the 2009 Plan, and the related weighted average grant date fair value, for 2018, 2017 and 2016:

	RSUs & PRSUs Outstanding
	Number of Shares			Weighted Average Grant Date Fair Value
	(in thousands)
Nonvested at January 3, 2016		1,435		$	2.30
Granted		1,822			0.97
Vested		(649	)		1.07
Forfeited		(1,238	)		—
Nonvested at January 1, 2017		1,370			1.68
Granted		1,852			1.41
Vested		(596	)		1.46
Forfeited		(263	)		—
Nonvested at December 31, 2017		2,363			1.54
Granted		1,539			0.85
Vested		(1,073	)		1.37
Forfeited		(259	)		—
Nonvested at December 30, 2018		2,570		$	1.23

Summary of the fair value of rights issued pursuant to ESPP

The fair value of rights issued pursuant to the Company’s ESPP was estimated on the commencement date of each offering period using the following weighted average assumptions:

	Fiscal Years
	2018			2017			2016
Expected life (months)	6.0				6.1			6.1
Risk-free interest rate		2.26	%		1.22	%		0.97	%
Volatility		50	%		53	%		59	%
Dividend yield		—			—			—